Skip to main content
Erschienen in: PharmacoEconomics 1/2009

01.01.2009 | Original Research Article

Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data

verfasst von: Prof. Ulf-G Gerdtham, Philip Clarke, Alison Hayes, Soffia Gudbjornsdottir

Erschienen in: PharmacoEconomics | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and aims: To estimate short- and long-term costs of inpatient hospitalization in Sweden for major diabetes mellitus-related events.
Materials and methods: Costs were estimated using administrative hospital data from the Swedish National Board of Health and Welfare, which is linked to the Swedish National Diabetes Register. Data were available for 179 749 patients with diabetes in Sweden from 1998 to 2003 (mean and median duration of 6 years’ follow-up). Costing of inpatient admissions was based on Nordic diagnosis-related groups (NordDRG). Multiple regression analysis (linear and generalizing estimating equation models) was used to estimate inpatient care costs controlling for age, sex and co-morbidities. The data on hospitalizations were converted to costs (€) using 2003 exchange rates.
Results: The average annual costs (linear model) associated with inpatient admissions for a 60-year-old male in the year the first event first occurred were as follows: €6488 (95% CI 5034, 8354) for diabetic coma; €6850 (95% CI 6514, 7204) for heart failure; €7853 (95% CI 7559, 8144) for non-fatal stroke; €8121 (95% CI 7104, 9128) for peripheral circulatory complications; €8736 (95% CI 8474, 9001) for non-fatal myocardial infarction (MI); €10 360 (95% CI 10 085, 10 643) for ischaemic heart disease; €11 411 (95%CI 10 298, 12 654) for renal failure; and €14 949 (95% CI 13 849, 16 551) for amputation. On average, the costs were higher when co-morbidity was accounted for (e.g. MI with co-morbidity was twice as costly as MI alone).
Conclusions: Average hospital inpatient costs associated with common diabetes-related events can be estimated using panel data regression methods. These could assist in modelling of long-term costs of diabetes and in evaluating the cost effectiveness of improving care.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Total healthcare expenditure is financed through four different sources: county council taxes (60.0%), social insurance (17.8%), grants from the state (11.9%) and direct consumer charges (10.3%).[10]
 
Literatur
1.
Zurück zum Zitat American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004; 27: 2262–5CrossRef American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004; 27: 2262–5CrossRef
2.
Zurück zum Zitat Norlund A, Apelqvist J, Bitzen PO, et al. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med 2001 Jul; 250 (1): 57–65PubMedCrossRef Norlund A, Apelqvist J, Bitzen PO, et al. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med 2001 Jul; 250 (1): 57–65PubMedCrossRef
3.
Zurück zum Zitat Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Int Med 1999; 159: 1873–80CrossRef Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Int Med 1999; 159: 1873–80CrossRef
4.
Zurück zum Zitat Clarke PM, Gray A, Briggs A, et al., on behalf of the UK Prospective Diabetes Study (UKPDS 72). Cost utility analyses of intensive blood-glucose and tight blood-pressure control in type 2 diabetes. Diabetologia 2005 May; 48 (5): 868–77PubMedCrossRef Clarke PM, Gray A, Briggs A, et al., on behalf of the UK Prospective Diabetes Study (UKPDS 72). Cost utility analyses of intensive blood-glucose and tight blood-pressure control in type 2 diabetes. Diabetologia 2005 May; 48 (5): 868–77PubMedCrossRef
5.
Zurück zum Zitat Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 68) Outcomes Model. Diabetologia 2004; 47: 1747–59PubMedCrossRef Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 68) Outcomes Model. Diabetologia 2004; 47: 1747–59PubMedCrossRef
6.
Zurück zum Zitat Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (type 1 and 2) to support clinical and reimbursement decision-making. Cur Med Res 2004; 20: S5–26CrossRef Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (type 1 and 2) to support clinical and reimbursement decision-making. Cur Med Res 2004; 20: S5–26CrossRef
7.
Zurück zum Zitat Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on health care costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442–50PubMedCrossRef Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on health care costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442–50PubMedCrossRef
8.
Zurück zum Zitat O’Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications from type 2 diabetes mellitus in the US. Diabetes Care 1998; 21: 1122–8PubMedCrossRef O’Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications from type 2 diabetes mellitus in the US. Diabetes Care 1998; 21: 1122–8PubMedCrossRef
9.
Zurück zum Zitat Clarke P, Kelman C, Colagiuri S. Factors influencing the cost of hospital care for people with diabetes in Australia. J Diabetes Complications 2006; 20 (6): 349–55PubMedCrossRef Clarke P, Kelman C, Colagiuri S. Factors influencing the cost of hospital care for people with diabetes in Australia. J Diabetes Complications 2006; 20 (6): 349–55PubMedCrossRef
10.
Zurück zum Zitat Gerdtham U-G. The impact of aging of health care expenditure in Sweden. Health Policy 1993; 24: 1–8PubMedCrossRef Gerdtham U-G. The impact of aging of health care expenditure in Sweden. Health Policy 1993; 24: 1–8PubMedCrossRef
11.
Zurück zum Zitat Anell A. Swedish healthcare under pressure. Health Econ 2005; 14: Anell A. Swedish healthcare under pressure. Health Econ 2005; 14:
12.
Zurück zum Zitat Gudbjorrnsdottir S, Cederholm S, Nilsson PM, et al. Swedish National Diabetes Register, the national diabetes register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003; 26 (4): 1270–6CrossRef Gudbjorrnsdottir S, Cederholm S, Nilsson PM, et al. Swedish National Diabetes Register, the national diabetes register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003; 26 (4): 1270–6CrossRef
14.
Zurück zum Zitat Hsiao C. Analysis of panel data. 2nd ed. Cambridge: Cambridge University Press, 2003CrossRef Hsiao C. Analysis of panel data. 2nd ed. Cambridge: Cambridge University Press, 2003CrossRef
15.
Zurück zum Zitat Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organizational Research Methods 2004; 7 (2): 127–50CrossRef Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organizational Research Methods 2004; 7 (2): 127–50CrossRef
16.
Zurück zum Zitat Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6 (1): 93–109PubMedCrossRef Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6 (1): 93–109PubMedCrossRef
18.
Zurück zum Zitat Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293–301PubMedCrossRef Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293–301PubMedCrossRef
20.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
21.
Zurück zum Zitat Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden. J Int Med 1998; 244 (6): 461–8CrossRef Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden. J Int Med 1998; 244 (6): 461–8CrossRef
22.
Zurück zum Zitat Clarke P, Leal J, Kelman C, et al. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health 2008; 11 (2): 199–206.PubMedCrossRef Clarke P, Leal J, Kelman C, et al. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health 2008; 11 (2): 199–206.PubMedCrossRef
23.
Zurück zum Zitat National Diabetes Register [online]. Available from URL: https://www.ndr.nu/ [Accessed 2008 Nov 25] National Diabetes Register [online]. Available from URL: https://​www.​ndr.​nu/​ [Accessed 2008 Nov 25]
Metadaten
Titel
Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data
verfasst von
Prof. Ulf-G Gerdtham
Philip Clarke
Alison Hayes
Soffia Gudbjornsdottir
Publikationsdatum
01.01.2009
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 1/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200927010-00008

Weitere Artikel der Ausgabe 1/2009

PharmacoEconomics 1/2009 Zur Ausgabe